Related Experiment Videos
[Clinico-hematological effectiveness in losartan for treating hypertensive patients]
Insights
Lozartan effectively treats hypertension by reducing blood pressure and improving heart function. This 6-week monotherapy showed no adverse effects in patients with mild to moderate hypertensive disease.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Context:
- Hypertensive disease (HD) affects systemic hemodynamics and cardiac structure.
- Left ventricular (LV) hypertrophy is a common complication of untreated hypertension.
- Metabolic disturbances in lipid, carbohydrate, and purine metabolism are associated with HD.
Purpose:
- To evaluate the effects of 6-week losartan monotherapy (50 mg daily) on hemodynamic, cardiac, metabolic, and renal parameters in patients with mild to moderate HD.
- To assess the impact of losartan on 24-hour arterial pressure (AP) monitoring, including nocturnal and early morning readings.
- To determine the safety and efficacy of losartan in this patient cohort.
Summary:
- Losartan monotherapy significantly reduced total peripheral resistance without causing reflex tachycardia.
- The treatment decreased nocturnal and early morning AP, indicating improved overall blood pressure control.
- Losartan enhanced myocardial contractile and pumping function, leading to regression of LV hypertrophy.
- No adverse side effects were attributed to losartan during the 6-week study period.
Impact:
- Losartan is an effective antihypertensive medication for mild to moderate hypertensive disease.
- The drug offers benefits beyond blood pressure reduction, including cardiac remodeling and improved heart function.
- The absence of side effects suggests a favorable safety profile for losartan in managing hypertension.
Abstract:
Effects were studied of a 6-week lozartan monotherapy, 50 mg daily, on the systemic hemodynamics, morphofunctional characteristics of the left ventricle (LV), lipid, carbohydrate, purin metabolisms, and some parameters characterizing renal function in patients with mild and moderately severe hypertensive disease (HD). A 24-h monitoring of arterial pressure (AP) was conducted in the above patients. Lozartan proved to be effective hypertensive medication in mild and moderately severe HD, capable of decreasing significantly total peripheral resistance with no reflex tachycardia developing. The drug has been shown to reduce nightly "pressure load" and AP in the small hours as well, and to improve the contractile and pumping function of the myocardium making for regression of LV hypertrophy, with no side effects noted.